New Alzheimer's Treatment Slows Decline, But Comes at a High Cost

Australia's Therapeutic Goods Administration (TGA) approved a new drug for early Alzheimer's disease: lecanemab, sold under the brand name Leqembi. It follows the approval of a similar drug, donanemab, earlier this year. But while lecanemab has been shown to slow the progression of disease in some people who receive an early diagnosis, it comes with a high price tag that will put it out of reach for many people worldwide.